1051 ET - There will be a debate around how conservative Doximity's guidance is until the company's typical upselling season kicks off in August, JPMorgan analysts say in a research note. At that point, Doximity will have better clarity into how the budgets of its pharmaceutical clients are shaping up, the analysts say. As of right now, the company's outlook assumes some weakness in cross-selling and upselling, they say. But management says it hasn't seen any indications yet of its market slowing, and that Doximity faces less risk than it used to now that just under 70% of the year's revenue is already under contract, the analysts say. (dean.seal@wsj.com)
(END) Dow Jones Newswires
May 16, 2025 10:51 ET (14:51 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。